- Home
- FluxMPS™ Iscove's Modified Dulbecco's Medium (IMDM), Low Glucose with 25mM HEPES w/o Phenol Red: 1X Liquid
FluxMPS™ Iscove's Modified Dulbecco's Medium (IMDM), Low Glucose with 25mM HEPES w/o Phenol Red: 1X Liquid
A Microfluidics Suitable, low-glucose Iscove's Modified Dulbecco's Medium (IMDM) re-engineered for microphysiological systems and microfluidic channels. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.
- Nano-filtered, microchannel-safe formulation engineered for microphysiological systems (MPS) and organ-on-a-chip (OoC) platforms
- FluxMPS™ Quadruple-stage filtration architecture (0.1 µm ×2 + 0.04 µm ×2) for ultra-low particulate, sub-mycoplasma-scale polishing
- Endotoxin release specification < 0.05 EU/mL by USP <85> BET, controlled per manufacturing batch
- Iscove's Modified Dulbecco's Medium (low-glucose, 2 g/L); HEPES-buffered (25 mM) with 36 mM sodium bicarbonate, phenol red-free
- Formulated with Ultrapure Type 1 water (18.2 MΩ·cm) for ultra-clean microfluidic perfusion
- ISO Class 5 (Class 100) aseptic fill & finish under an ISO 13485:2016 quality management system
- pH, glucose concentration, salts, HEPES, and nutrient composition available on request
- Glucose2000.000 mg/L
- L-Glutamine584.000 mg/L
- Sodium Pyruvate110.000 mg/L
- pH (USP <791>)7.4
- Osmolality (USP <785>)280 – 320 mOsm/kg H₂O
- Endotoxin< 0.05 EU/mL
- FiltrationQuadruple-stage (0.1 µm ×2 + 0.04 µm ×2)
- Storage2–8 °C, protected from light
- Shelf Life12 months from date of manufacture, unopened
- ShippingCold-pack
Engineered where standard 0.22 µm media fails
Conventional 0.22 µm-filtered media can carry subvisible particulates and mycoplasma-scale contaminants (0.2–0.3 µm) that accumulate in microfluidic channels, corrupt biosensor signals, and shorten perfusion runs. FluxMPS™ IMDM, Low Glucose + 25mM HEPES w/o Phenol Red is re-engineered for these microphysiological systems.[1,2]
Microchannel-safe purity
A 0.04 µm final-polish filter targets subvisible particulates per USP <788> Method 1 (light obscuration), reducing the microchannel accumulation and clogging that degrade organ-on-a-chip experiments.
Total metabolic control
A defined carbon-source and nutrient backbone (glucose, L-glutamine, sodium pyruvate) supports Warburg-effect and metabolic-flux studies where standard serum-rich media confound the readout.
Ultrapure-grade water
Formulated with Ultrapure Type 1 water (18.2 MΩ·cm), reducing trace-metal and organic-carbon (TOC) background for consistent culture performance.
Low background for imaging
Ultra-low particulate baseline from the 0.04 µm final filter reduces optical scatter for confocal microscopy, biosensors, and TEER measurements. (Riboflavin is present in this formulation and contributes its own native fluorescence, which filtration does not remove.)
Rich, stable nutrient profile
IMDM's enriched amino-acid and vitamin profile, selenium, and sodium pyruvate are released on a micro-batch basis for lot-to-lot consistency.
Customization on demand
pH, glucose, salts, HEPES, and nutrient composition can be adjusted on request — contact support@diagnocine.com.
Quadruple-stage filtration system
The FluxMPS™ purity architecture is built around a four-stage membrane train (0.1 µm ×2 + 0.04 µm ×2), positioning DCP-IMDMLGH-R1X as a ready-to-use, ultra-clean medium for microfluidic and organ-on-a-chip work at a purity level significantly exceeding conventional 0.22 µm media.[2,3]
-
1
0.1 µmPrefiltration I
Large particulate, cell debris and protein aggregate removal; protects the first 0.04 µm cartridge.
-
2
0.04 µmFinal filtration I
First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass a 0.22 µm filter.
-
3
0.1 µmPrefiltration II
Second dedicated prefilter, protecting the second 0.04 µm cartridge.
-
4
0.04 µmFinal filtration II — Polish
Ultimate polishing filter; aseptic fill under an ISO Class 5 (Class 100) environment.
Performance vs. conventional media
© Diagnocine® — DCP-IMDMLGH-R1X
Built for microphysiological & organ-on-a-chip research
IMDM, Low Glucose + 25mM HEPES w/o Phenol Red supports rapidly proliferating, high-density cultures — from erythroid progenitors, macrophages, and B/T lymphocytes to hybridomas — and is well suited to perfused MPS, metabolic, and imaging applications.[1,4]
Automated Bioreactors & Robotics
For automated bioreactors and robotic perfusion platforms, an optional MPS Grade 0.01 µm (10 nm) six-stage ultra nano-filtered variant is available, adding 0.02 µm and 0.01 µm stages after this product's standard 0.04 µm polish, to push particulate exclusion further.
- Total particulate exclusion for narrow microchannels and high-resolution optics
- Valve & sensor protection across long unattended runs
- Extended perfusion stability for multi-week organ-on-a-chip experiments
Inquiry Required: the optional MPS Grade 0.01 µm (10 nm) variant is made to order — contact support@diagnocine.com to request it.
Micro Physiological System (MPS) & Chip
Ultra-low-particulate fluid for perfused chips and barrier models.
Warburg Effect & Metabolic Research
Defined carbon-source backbone for tumor-metabolism studies.
iPSC-Derived Models
Consistent nutrient profile for differentiated iPSC cultures.
Endothelial & Primary Cells
Nutrient-rich medium for vessel-on-chip and primary cells.
Metabolic Flux Analysis
Clean baseline for tracer and respirometry workflows. Not compatible with Agilent Seahorse XF assays, which require bicarbonate-free, phenol red-free medium; this formulation contains 36 mM sodium bicarbonate.
Microscopy & Optical Sensing
Low particulate baseline for long-term imaging.
Technical specifications
Representative specifications for DCP-IMDMLGH-R1X. Values are confirmed per batch on the Certificate of Analysis.
| Parameter | Specification |
|---|---|
| Formulation | Iscove's Modified Dulbecco's Medium (IMDM), 1X liquid (+25 mM HEPES, w/o phenol red); contains L-Glutamine, Sodium Bicarbonate, Calcium, Magnesium, Glucose, Sodium Pyruvate |
| Appearance | Pale-yellow colored, clear solution (phenol red-free) |
| pH USP <791> | 7.4 |
| Osmolality USP <785> | 280 – 320 mOsm/kg H₂O |
| Glucose | 2000.000 mg/L |
| L-Glutamine | 584.000 mg/L |
| Sodium Pyruvate | 110.000 mg/L |
| Phenol Red | Not included |
| Parameter | Specification |
|---|---|
| Endotoxin USP <85> BET | < 0.05 EU/mL (batch release specification) |
| Sterility USP <71> | Filtered 0.1-micron membrane TWICE and 0.04-micron membrane TWICE. No bacterial or fungal growth observed after 14 days of incubation, per USP <71>. |
| Mycoplasma | 0.1 µm mycoplasma-retentive filtration (not tested per lot) |
| Particulate ≥10 µm USP <788> | Meets USP <788> Method 1 (light obscuration) limits |
| Particulate ≥25 µm USP <788> | Meets USP <788> Method 1 (light obscuration) limits |
| Water purity | Ultrapure Type 1 (18.2 MΩ·cm) |
| Manufacturing std. ISO | ISO 13485:2016; 21 CFR Part 820 (QMSR) aligned |
| Fill environment | ISO Class 5 (Class 100) aseptic |
| Parameter | Specification |
|---|---|
| Storage temperature | 2–8 °C, away from bright light |
| Freeze-thaw | Avoid repeated freeze-thaw |
| Shelf life | 12 months from date of manufacture, unopened |
| Shipping condition | Cold-pack |
| CO₂ requirement | Approximately 8% CO₂ (derived from 36 mM sodium bicarbonate at pH 7.4; 25 mM HEPES provides supplemental buffering) |
| Parameter | Specification |
|---|---|
| Raw material grade | Cell-culture grade, traceable lots |
| Traceability | Full lot traceability with CoA |
| Manufacturing QMS | ISO 13485:2016 certified facility |
| UNSPSC | 41116155 — Molecular biology and cell culture growth media (UNv260801) |
| Regulatory alignment | 21 CFR Part 820 (QMSR) aligned; For Research Use Only (RUO) |
| Production method | Micro-batch, ISO Class 5 fill & finish |
| Intended use | For Research Use Only (RUO) |
Full composition (mg/L)
Complete defined formulation of DCP-IMDMLGH-R1X, released on a per-batch basis. All 41 components and their mg/L values are reproduced from the validated formulation.
| Component | CAS Number | mg/L |
|---|---|---|
| INORGANIC SALTS | ||
| Calcium chloride dihydrate | 10035-04-8 | 219.000 |
| Magnesium sulfate anhydrous | 7487-88-9 | 97.720 |
| Potassium chloride | 7447-40-7 | 330.000 |
| Potassium nitrate | 7757-79-1 | 0.076 |
| Sodium bicarbonate | 144-55-8 | 3024.000 |
| Sodium chloride | 7647-14-5 | 4505.000 |
| Sodium dihydrogen phosphate anhydrous | 7558-80-7 | 109.000 |
| Sodium selenite | 10102-18-8 | 0.0173 |
| Component | CAS Number | mg/L |
|---|---|---|
| AMINO ACIDS | ||
| Glycine | 56-40-6 | 30.000 |
| L-Alanine | 56-41-7 | 25.000 |
| L-Arginine hydrochloride | 1119-34-2 | 84.000 |
| L-Asparagine | 70-47-3 | 25.000 |
| L-Aspartic acid | 56-84-8 | 30.000 |
| L-Cystine dihydrochloride | 30925-07-6 | 91.240 |
| L-Glutamic acid | 56-86-0 | 75.000 |
| L-Glutamine | 56-85-9 | 584.000 |
| L-Histidine hydrochloride monohydrate | 5934-29-2 | 42.000 |
| L-Isoleucine | 73-32-5 | 104.800 |
| L-Leucine | 61-90-5 | 104.800 |
| L-Lysine hydrochloride | 657-27-2 | 146.200 |
| L-Methionine | 63-68-3 | 30.000 |
| L-Phenylalanine | 63-91-2 | 66.000 |
| L-Proline | 147-85-3 | 40.000 |
| L-Serine | 56-45-1 | 42.000 |
| L-Threonine | 72-19-5 | 95.200 |
| L-Tryptophan | 73-22-3 | 16.000 |
| L-Tyrosine disodium salt | 69847-45-6 | 104.200 |
| L-Valine | 72-18-4 | 93.600 |
| Component | CAS Number | mg/L |
|---|---|---|
| VITAMINS | ||
| Choline chloride | 67-48-1 | 4.000 |
| D-Biotin | 58-85-5 | 0.013 |
| D-Ca-Pantothenate | 137-08-6 | 4.000 |
| Folic acid | 59-30-3 | 4.000 |
| Nicotinamide | 98-92-0 | 4.000 |
| Pyridoxal hydrochloride | 65-22-5 | 4.000 |
| Riboflavin | 83-88-5 | 0.400 |
| Thiamine hydrochloride | 67-03-8 | 4.000 |
| Vitamin B12 | 68-19-9 | 0.013 |
| i-Inositol | 87-89-8 | 7.200 |
| OTHERS | ||
| D-Glucose | 50-99-7 | 2000.000 |
| HEPES | 7365-45-9 | 5958.000 |
| Sodium pyruvate | 113-24-6 | 110.000 |
Manufacturing & compliance
All final packaging, quality assurance, and testing for DCP-IMDMLGH-R1X are completed at the Diagnocine R&D and Quality Testing Center; customization and assembly are performed at Diagnocine Precision, Totowa, New Jersey, USA.
ISO 13485:2016 QMS
Manufactured under an ISO 13485:2016 quality management system, 21 CFR Part 820 (QMSR) aligned.
Ultrapure Type 1 Water
Formulated with 18.2 MΩ·cm Ultrapure Type 1 water for ultra-low ionic and organic background.
ISO Class 5 Fill & Finish
Final 0.04 µm polish and aseptic fill performed in an ISO Class 5 (Class 100) environment.
Micro-Batch Precision
Micro-batch production with per-batch release testing for lot-to-lot consistency and traceability.
Endotoxin — USP <85> BET
Bacterial endotoxin (LAL) testing to a < 0.05 EU/mL release specification, controlled per manufacturing batch.
Particulate — USP <788> Method 1
Subvisible particulate matter controlled to USP <788> Method 1 (light obscuration) limits.
Osmolality — USP <785>
Osmolality verified per batch within the specified range.
Documentation / CoA
A Certificate of Analysis accompanies every batch with measured QC values.
- Endotoxin — LAL assay, USP <85> Bacterial Endotoxins Test; assay sensitivity 0.005 EU/mL; release specification < 0.05 EU/mL
- pH, osmolality, conductivity, appearance and clarity
- Sterility
How DCP-IMDMLGH-R1X compares
DCP-IMDMLGH-R1X versus conventional 0.22 µm-filtered IMDM and a standard 0.22 µm-filtered DMEM-class alternative.
| Parameter | DCP-IMDMLGH-R1X (FluxMPS™) | Conventional IMDM (0.22 µm) | Standard DMEM-class (0.22 µm) |
|---|---|---|---|
| Grade | Microfluidics Suitable (0.04 µm final) | Standard grade (0.22 µm) | Standard grade (0.22 µm) |
| Formulation enrichment | Iscove-enriched amino acids/vitamins + selenium, potassium nitrate | IMDM base | DMEM base |
| Final filtration pore size | 0.04 µm (40 nm) | 0.22 µm | 0.22 µm |
| Number of filtration stages | 4 (0.1 µm ×2 + 0.04 µm ×2) | 1 | 1 |
| Mycoplasma barrier filtration | check_circle | cancel | cancel |
| Endotoxin (release specification) | < 0.05 EU/mL | Corning classical liquid media — < 0.25 EU/mL Sigma-Aldrich DMEM complete medium — ≤ 2 EU/mL Gibco classical DMEM — Not specified (recorded per lot) |
|
| USP <788> particulate compliance | check_circle | cancel | cancel |
| Water quality | Ultrapure Type 1 (18.2 MΩ·cm) | Type 1/2 | Type 1/2 |
| Manufacturing QMS | ISO 13485:2016 | Varies | Varies |
| Microfluidic channel compatibility | check_circle | Limited | Limited |
| Custom formulation | check_circle | Limited | Limited |
Comparison figures from published supplier specifications, accessed 2 September 2026. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".
Frequently asked questions
Common questions about DCP-IMDMLGH-R1X for microphysiological and standard cell-culture workflows.
Supporting literature
Peer-reviewed literature supporting the use of enriched, ultra-filtered media in microphysiological and metabolic research.
- Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–772.doi:10.1038/nbt.2989
- Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development. Cell Stem Cell. 2018;22(3):310–324.doi:10.1016/j.stem.2018.02.011
- Halldorsson S, et al. Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices. Biosens Bioelectron. 2015;63:218–231.doi:10.1016/j.bios.2014.07.029
- Iscove NN, Melchers F. Complete replacement of serum by albumin, transferrin, and soybean lipid in cultures of lipopolysaccharide-reactive B lymphocytes. J Exp Med. 1978;147(3):923–933.doi:10.1084/jem.147.3.923
- Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.doi:10.1126/science.1160809
- Nikolaev M, et al. Homeostatic mini-intestines through scaffold-guided organoid morphogenesis. Nature. 2020;585(7826):574–578.doi:10.1038/s41586-020-2724-8
- Drexler HG, Uphoff CC. Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology. 2002;39(2):75–90.doi:10.1023/A:1022913015916
- Booth R, Kim H. Characterization of a microfluidic in vitro model of the blood-brain barrier. Lab Chip. 2012;12(10):1784–1792.doi:10.1039/c2lc40094d
- Whitesides GM. The origins and the future of microfluidics. Nature. 2006;442(7101):368–373.doi:10.1038/nature05058
- Low LA, Mummery C, Berridge BR, et al. Organs-on-chips: into the next decade. Nat Rev Drug Discov. 2021;20(5):345–361.doi:10.1038/s41573-020-0079-3

